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(3) Temporal relationship. (Initiation or
enhancement of the event should clearly
precede major, ischemia-induced cell
death.) 
(4) Topographic relationship. (Brain
areas that suffer the greatest cell damage
should also demonstrate the greatest
changes in the event.)
(5) Dose relationship. (Ischemic situ-
ations or circumstances that produce
greater brain damage should also exhibit
larger changes in the event.)
(6) Modulatory neuroprotection. (In-
hibiting the event, or otherwise blocking
its effects, should decrease the degree of
ischemic damage.)
The intracellular events purported to
have a role in the pathogenesis of stroke
should be considered in the context of
this or a similar list. Frequently, when one
applies these criteria only to a particular
biochemical event, its relationship to the
ensuing neuronal damage becomes sig-
nificantly less clear. For example, one of
the earliest events in ischemia is a Ca21-
dependent increase in lipid hydrolytic
enzyme activity3, which includes the for-
mation and accumulation of free fatty
acids, such as arachidonic acid, free radi-
cals, thromaboxanes, prostaglandins and
leukotrienes. All of these compounds
have been suggested to have roles in cell
damage and it has been proposed that
reducing lipase activity represents a viable
means of reducing stroke-related damage.
Despite the evidence that free fatty acid
accumulation leads to cell death, there
are several inconsistencies in this theory.
Non-ischemic situations in which free fatty
acids accumulate are not associated with
cell death4 and free fatty acid levels can
remain unchanged after treatments that
attenuate ischemic damage5. Moreover,
pharmacological inhibition of lipid peroxi-
dation does not completely prevent cell
death, suggesting that at best, the accumu-
lation of free fatty acids has a partial role
in ischemia-induced cell death6–10. A closer
examination of the biochemistry of stroke
is likely to uncover similar inconsistencies.
Despite the critique of animal models by
DeKeyser et al., such experimental tools
are fundamentally important in the selection
of clinical leads. Although animal models
cannot mimic the complex etiology and
pathophysiology of human conditions, they
do provide a practical way to answer ques-
tions concerning biochemistry and function.
In the case of stroke, such models can be
used to address the specific issues outlined
above. Their continued refinement should
also be a priority of investigators. Rather
than adopting the attitude that models have
no predictive value, efforts should be di-
rected at mimicking the human condition,
by aiming for a better understanding of the
relationship between the biochemical events
and cell damage in stroke, and obtaining a
detailed assessment of the behavioral effects
of the stroke and the effects of treatments
on those deficits.
Finally, the authors discussion of the
manner in which pharmaceutical companies
conduct research and clinical trials is mis-
directed. The statement ‘but there is often
so much pressure from senior management
in pharmaceutical companies to rush for
registration that well-conducted Phase II
trials are often neglected’ clearly places the
blame for clinical failures on the expecta-
tions and ethics of corporate management.
Are the authors suggesting that given the
time and expense to get a drug to the point
of Phase II clinical evaluation, that compa-
nies would be willing to do less than maxi-
mize the possibility of obtaining an accurate
measure of the potential of the drug? Do
they really mean to suggest that the pres-
sure to gain drug approval forces otherwise
excellent researchers to act hastily and
unethically? Of course pressure to make
decisions exists. It exists because of the
time and expense in developing treatments
and it exists because individuals need effec-
tive treatments. Every effort should be made
to determine the potential of a drug in as
timely a manner as possible. There are very
few second chances and it would be foolish
to allow pressure to result in anything other
than the best possible trial design at the time.
Moreover, as the trials are not conducted
by ‘senior management’, only overseen and
financially supported, the authors criticism
seems too narrowly directed.
Dwaine F. Emerich
Alkermes Inc., 
Cambridge, MA 02139, USA.
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Reply
Emerich correctly points out that not all of
the biochemical events that occur during
focal brain ischaemia contribute to cell
death1. Some events might be merely epi-
phenomena. However, the compounds that
have been investigated in pivotal clinical trials
were selected on the basis of their neuro-
protective properties in preclinical experi-
ments. The animal models are therefore
indispensable. Nevertheless, one should not
expect anything more from these animal
models than an indication that a compound
has neuroprotective properties, and we sin-
cerely believe that all efforts directed at
mimicking the human condition are a waste
of time and money. The animal experiments
should not necessarily be predictive for the
human situation.
Emerich is also correct in stating that
every effort should be made to determine
the potential of a drug in as timely a manner
as possible. Once the neuroprotective
properties and an acceptable safety profile
of a compound have been established, one
should immediately go to so called ‘proof of
concept’ studies in individuals who have suf-
fered a stroke. This implies that adequate
Phase II studies must be carried out to
determine the optimal tolerated dosages,
therapeutic time window and duration of
therapy. Such information can now be ob-
tained from a small number of individuals by
using imaging techniques that visualize a
potentially salvageable penumbra, such as
combined diffusion weighted and perfusion
MRI (Ref. 2). We should maximally exploit
these tools in order to design Phase III trials
that have a better chance of success.
Jacques De Keyser
Geert Sulter
Dept of Neurology, 
Academisch Ziekenhuis Groningen, 
9700 RB Groningen, The Netherlands.
Paul G. Luiten
Dept of Animal Physiology, 
Biological Center, Rijksuniversiteit
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